https://www.yumab.com/2025/02/19/vhh-discovery-for-bispecifics/
VHH discovery for bispecifics - combination of in-vivo immunization and in-vitro display - Yumab
Feb 19, 2025 - Conventional IgG antibodies are powerful tools for many applications. Despite their flexibility, they also encounter limits of feasibility. With their size of...
https://www.sinodrugwatch.com/beyond-ivonescimab-chinas-next-billion-pd-1-vegf-bispecific-licensing-opportunities/
Emerging Chinese PD-1/VEGF Bispecifics: Licensing & Market Outlook
Aug 27, 2025 - With blockbuster deals by 3SBio, BioNTech, and Akeso, emerging Chinese PD-1/VEGF bispecifics like RC148, HB0025, JS207, and CS2009 are primed for...
emergingchinesepdbispecificslicensing
https://biz.chosun.com/en/en-science/2026/03/08/LL3JWREKZZAN5IWYDKUS67T6ZU/
Bispecifics challenge CAR-T as Korea reshapes DLBCL reimbursement battle - CHOSUNBIZ
Mar 7, 2026 - Bispecifics challenge CAR-T as Korea reshapes DLBCL reimbursement battle Pricing power shifts to fixed-duration Columvi as Epkinlys OS miss clouds tal
challenge carbispecifics
https://www.leukocare.com/blog/formulation-approaches-for-tandem-scfv-bispecifics
Formulation Approaches for Tandem scFv Bispecifics | Leukocare
Guide for drug product leaders on formulation approaches for tandem scFv bispecifics. Tackle stability, aggregation, and fragmentation. Learn more!
formulationapproachestandembispecifics
https://www.cancernetwork.com/view/sequencing-therapies-for-relapsed-refractory-multiple-myeloma-bispecifics-or-car-t-cell-therapy
Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy |...
May 17, 2026 - Panelists discuss how to optimize the sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma, considering factors...